iOnctura appoints Paul Sekhri as Chair of its Board of Directors

/in
  • Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization
  • Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled
  • Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing
Geneva, Switzerland and Amsterdam, The Netherlands and Cambridge, Massachusetts, USA, October 15, 2026 – iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, today announces the appointment of Paul Sekhri as Chair of its Board of Directors with immediate effect.
© Optimum Strategic Communications.
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of...R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN...